| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 61786-0230-19 | 61786-0230 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 17, 2015 | Mar 25, 2017 | No Longer Used |
| 72603-0198-01 | 72603-0198 | Zoledronic acid | Zoledronic acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Nov 1, 2023 | In Use | ||
| 70121-1694-02 | 70121-1694 | Plerixafor | Plerixafor | 24.0 mg/1.2mL | Ancillary Therapy | Immunostimulant | Stem Cell Mobilizer | Subcutaneous | Jul 25, 2023 | In Use | |
| 00006-4119-03 | 00006-4119 | Human Papillomavirus 9-valent Vaccine, Recombinant | GARDASIL 9 | 40.0 ug/.5mL, 60.0 ug/.5mL, 40.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 20.0 ug/.5mL, 30.0 ug/.5mL | Ancillary Therapy | Protective Agent | HPV Vaccine | Intramuscular | Dec 10, 2014 | In Use | |
| 00409-4760-13 | 00409-4760 | Ondansetron Hydrochloride and Dextrose | Ondansetron Hydrochloride and Dextrose | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Feb 2, 2007 | Nov 1, 2011 | No Longer Used | |
| 55150-0126-20 | 55150-0126 | Ondansetron Hydrochloride | Ondansetron | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec 21, 2012 | In Use | |
| 52125-0569-38 | 52125-0569 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 27, 2013 | May 8, 2016 | No Longer Used |
| 00173-0489-00 | 00173-0489 | Ondansetron Hydrochloride | Zofran | 4.0 mg/5mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Feb 5, 1997 | Jun 30, 2019 | No Longer Used |
| 60505-0744-06 | 60505-0744 | Ondansetron | Ondansetron | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec 26, 2006 | Mar 11, 2011 | No Longer Used | |
| 55513-0209-91 | 55513-0209 | Filgrastim | Neupogen | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct 2, 2000 | In Use | |
| 23155-0196-43 | 23155-0196 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jan 18, 2013 | Jul 31, 2020 | In Use |
| 70771-1347-09 | 70771-1347 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | May 16, 2018 | In Use | |
| 68094-0325-62 | 68094-0325 | Ondansetron Hydrochloride | Ondansetron Hydrochloride | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 11, 2010 | Oct 31, 2015 | No Longer Used | |
| 00185-0155-05 | 00185-0155 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Apr 18, 2005 | Mar 31, 2012 | No Longer Used | |
| 00703-7239-31 | 00703-7239 | Ondansetron and Dextrose | Ondansetron and Dextrose | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Nov 22, 2006 | Mar 31, 2011 | No Longer Used | |
| 61703-0325-18 | 61703-0325 | Pamidronate Disodium | Pamidronate Disodium | 6.0 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Jul 28, 2003 | In Use | ||
| 49884-0324-52 | 49884-0324 | Ondansetron | Zuplenz | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 5, 2010 | Sep 15, 2011 | No Longer Used | |
| 68001-0366-25 | 68001-0366 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Oct 5, 2018 | May 31, 2022 | No Longer Used | |
| 70121-1571-07 | 70121-1571 | Filgrastim | RELEUKO | 480.0 ug/1.6mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Feb 25, 2022 | In Use | |
| 47335-0715-88 | 47335-0715 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 25, 2022 | No Longer Used | |
| 42291-0280-90 | 42291-0280 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 26, 2013 | May 31, 2020 | In Use |
| 54569-6168-01 | 54569-6168 | Ondansetron, ondansetron hydrochloride | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 9, 2016 | In Use | |
| 55513-0209-20 | 55513-0209 | Filgrastim | Neupogen | 480.0 ug/.8mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Oct 1, 2025 | In Use | |
| 57237-0077-30 | 57237-0077 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 12, 2010 | In Use | |
| 63187-0199-10 | 63187-0199 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 1, 2014 | In Use |
Found 11888 results — Export these results
Home